专用静脉支架治疗梗阻性慢性深静脉疾病的系统综述与荟萃分析
本系统综述与荟萃分析纳入16项单臂观察性研究共1688例患者,评估专用静脉支架治疗梗阻性慢性深静脉疾病的有效性与安全性。结果显示12个月汇总一期和二期通畅率分别为74.0%和90.4%,症状和生活质量改善,出血并发症少见。
要点
- 专用静脉支架治疗梗阻性慢性深静脉疾病12个月汇总一期通畅率74.0%、二期通畅率90.4%。
- 支架术后疼痛、静脉性跛行和水肿持续改善,73.4%的溃疡愈合。
- 大出血和小出血发生率分别为1.9%和4.7%,杂交手术者出血更常见。
核心结论
- 专用静脉支架治疗梗阻性慢性深静脉疾病是安全的技术,在研究的局限性内与良好的通畅率和症状改善相关。
研究设计与样本
- 检索MEDLINE和Embase 2010年1月至2020年5月文献,最终纳入16项单臂观察性研究,共1688例患者。
- 70.5%的患者为血栓后综合征,其余为非血栓性髂静脉病变;使用8种不同品牌的专用静脉支架。
主要发现
- 末次随访时73.4%的溃疡愈合,疼痛、静脉性跛行和水肿持续改善,慢性静脉功能不全问卷-20显示健康相关生活质量显著改善。
- 最常报告的并发症为支架内闭塞(n=204)、支架内狭窄(n=149)和轻微出血(n=77)。
- 12个月一期通畅率范围59%至94%,二期通畅率范围87%至100%;汇总一期和二期通畅率分别为74.0%和90.4%。
- 大出血和小出血发生率分别为1.9%和4.7%,出血并发症在杂交手术患者中更常见。
临床怎么用
- 对于梗阻性慢性深静脉疾病,专用静脉支架可作为治疗选择,需关注支架内闭塞和狭窄风险。
- 杂交手术患者出血风险较高,围术期应加强出血监测。
局限性
- 纳入研究均为单臂观察性研究,缺乏对照组,证据等级有限。
- 部分研究未报告病变特征(7项研究,n=840),病变狭窄或闭塞状态报告不全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This review aims to summarise the efficacy and safety of dedicated venous stenting for the treatment of obstructive chronic deep venous disease. The approaches to stenting and post-procedural management of different vascular units are also highlighted. METHODS: MEDLINE and Embase were searched to identify relevant literature on dedicated venous stents published from January 2010 to May 2020. The patient population and study characteristics; procedural characteristics; and outcomes related to post-stenting symptoms, health-related quality of life, patency, and complications were analyzed. RESULTS: Sixteen single-arm observational studies were included from 2366 studies identified from key word searches. In total, 1688 patients were included, of which 70.5% had post-thrombotic syndrome and the remainder had nonthrombotic iliac vein lesions. Nine studies (n = 848) stated whether lesions were stenotic (36.6%) or occlusive (63.4%). Seven studies did not report the lesion characteristics (n = 840). Eight different dedicated venous stent brands were used. At the last follow-up, 73.4% of ulcers had healed. The remaining symptomatic changes were described narratively; sustained improvements in pain, venous claudication, and edema after stenting were observed. Significant post-stenting improvements in health-related quality of life were noted, as measured by the Chronic Venous Insufficiency Questionnaire-20 instrument. Overall, the most frequently reported complications were in-stent occlusion (n = 204), in-stent stenosis (n = 149), and minor bleeding (n = 77). At 12 months, the primary patency ranged from 59% to 94%, whereas the secondary patency ranged 87% to 100%. The pooled primary and secondary stent patency rates at 12 months were 74.0% and 90.4%, respectively. The incidence of major and minor bleeding was 1.9% and 4.7%, respectively; bleeding complications were more common in patients undergoing hybrid interventions. CONCLUSIONS: Deep venous stenting using dedicated venous stents is a safe technique to treat obstructive chronic deep venous disease and within the limitations of this study, is associated with good patency outcomes and symptomatic improvement.
引用
- Badesha AS, Bains PRS, Bains BRS, et al. A systematic review and meta-analysis of the treatment of obstructive chronic deep venous disease using dedicated venous stents. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33965610. doi:10.1016/j.jvsv.2021.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。